JP2014523398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523398A5 JP2014523398A5 JP2014501258A JP2014501258A JP2014523398A5 JP 2014523398 A5 JP2014523398 A5 JP 2014523398A5 JP 2014501258 A JP2014501258 A JP 2014501258A JP 2014501258 A JP2014501258 A JP 2014501258A JP 2014523398 A5 JP2014523398 A5 JP 2014523398A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- integrin
- beta
- antibody
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466791P | 2011-03-23 | 2011-03-23 | |
| US61/466,791 | 2011-03-23 | ||
| PCT/US2012/030204 WO2012129448A1 (en) | 2011-03-23 | 2012-03-22 | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523398A JP2014523398A (ja) | 2014-09-11 |
| JP2014523398A5 true JP2014523398A5 (enExample) | 2015-05-07 |
Family
ID=46879749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501258A Pending JP2014523398A (ja) | 2011-03-23 | 2012-03-22 | 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20140079637A1 (enExample) |
| EP (1) | EP2688585B1 (enExample) |
| JP (1) | JP2014523398A (enExample) |
| KR (1) | KR20140030153A (enExample) |
| CN (1) | CN103561761A (enExample) |
| AU (1) | AU2012230809B2 (enExample) |
| CA (1) | CA2830908C (enExample) |
| ES (1) | ES2699532T3 (enExample) |
| WO (1) | WO2012129448A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012129448A1 (en) * | 2011-03-23 | 2012-09-27 | The Regents Of The University Of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
| US10023638B2 (en) * | 2012-12-26 | 2018-07-17 | Oncosynergy, Inc. | Anti-integrin β1 antibody compositions and methods of use thereof |
| EP3067369A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the treatment of anti-angiogenic resistant cancer |
| EP3067698A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Pd-ecgf as biomarker of cancer |
| AU2016311298A1 (en) | 2015-08-25 | 2018-02-08 | Histide Ag | Compounds for inducing tissue formation and uses thereof |
| WO2017046229A1 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| DK3349778T3 (da) * | 2015-09-17 | 2021-11-22 | Histide Ag | Farmaceutisk association af vækstfaktorreceptoragonist og adhæsionsproteininhibitor til omdannelse af en neoplastisk celle til en ikke-neoplastisk celle og anvendelser deraf |
| KR20180050744A (ko) * | 2015-09-17 | 2018-05-23 | 히스티드 아게 | 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 |
| JP7222104B2 (ja) * | 2019-01-10 | 2023-02-14 | エスジー メディカル インコーポレイテッド | 抗ベータ１インテグリンヒト化抗体及びこれを含む癌治療用薬学組成物 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5272263A (en) * | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| US5840300A (en) | 1995-09-11 | 1998-11-24 | Trustees Of The University Of Pennsylvania | Methods and compositions comprising single chain recombinant antibodies |
| US5846536A (en) * | 1996-10-04 | 1998-12-08 | The Regents Of The University Of California | Restoration of normal phenotype in cancer cells |
| US6596276B1 (en) | 1997-09-30 | 2003-07-22 | Beth Israel Deaconess Medical Center | Method for inhibiting tumor angiogenesis in a living subject |
| DK1075277T4 (da) * | 1998-05-08 | 2012-12-17 | Univ California | Fremgangsmåder til detektion og inhibering af angiogenese |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US6716410B1 (en) | 1999-10-26 | 2004-04-06 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| JP3789066B2 (ja) | 1999-12-08 | 2006-06-21 | 三菱電機株式会社 | 液晶表示装置 |
| US8725620B2 (en) | 2000-07-10 | 2014-05-13 | Nobuyoshi Morimoto | System and method for negotiating improved terms for products and services being purchased through the internet |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2002097038A2 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
| EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
| AU2002365899B2 (en) | 2001-12-04 | 2007-09-13 | Onyx Pharmaceuticals, Inc. | RAF-MEK-ERK pathway inhibitors to treat cancer |
| DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| JP4932495B2 (ja) | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| US7618627B2 (en) * | 2004-06-03 | 2009-11-17 | The Regents Of The University Of California | Method of increasing radiation sensitivity by inhibition of beta one integrin |
| KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| JP4997432B2 (ja) | 2006-02-10 | 2012-08-08 | 学校法人慶應義塾 | 神経幹細胞の増殖抑制剤 |
| CA2646611A1 (en) * | 2006-03-21 | 2008-05-22 | Genentech, Inc. | Combinatorial therapy |
| SI1989231T1 (sl) * | 2006-03-21 | 2015-10-30 | Genentech, Inc., | Kombinacijska terapija, ki vključuje alfa5beta 1 antagoniste |
| WO2008031064A1 (en) * | 2006-09-07 | 2008-03-13 | University Of South Florida | Hyd1 peptides as anti-cancer agents |
| WO2009009114A2 (en) * | 2007-07-12 | 2009-01-15 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| WO2009018226A2 (en) * | 2007-07-27 | 2009-02-05 | Facet Biotech Corporation | Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e) |
| EP2060287B1 (de) * | 2007-11-14 | 2011-06-15 | BrainLAB AG | Medikamentenzuführungssystem für CED (Convection Enhanced Delivery)-Katheterinfusionen |
| US7928084B2 (en) * | 2008-08-20 | 2011-04-19 | New York Blood Center, Inc. | Regulation of integrin surface expression |
| CA2748161A1 (en) * | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
| JP6051048B2 (ja) * | 2009-03-25 | 2016-12-21 | ジェネンテック， インコーポレイテッド | 新規な抗α５β１抗体及びその使用 |
| WO2012129448A1 (en) * | 2011-03-23 | 2012-09-27 | The Regents Of The University Of California | Methods and compositions for improving antiangiogenic therapy with anti-integrins |
| US10023638B2 (en) * | 2012-12-26 | 2018-07-17 | Oncosynergy, Inc. | Anti-integrin β1 antibody compositions and methods of use thereof |
-
2012
- 2012-03-22 WO PCT/US2012/030204 patent/WO2012129448A1/en not_active Ceased
- 2012-03-22 US US14/006,669 patent/US20140079637A1/en not_active Abandoned
- 2012-03-22 KR KR1020137027236A patent/KR20140030153A/ko not_active Ceased
- 2012-03-22 JP JP2014501258A patent/JP2014523398A/ja active Pending
- 2012-03-22 EP EP12760157.3A patent/EP2688585B1/en active Active
- 2012-03-22 CA CA2830908A patent/CA2830908C/en active Active
- 2012-03-22 CN CN201280024596.8A patent/CN103561761A/zh active Pending
- 2012-03-22 AU AU2012230809A patent/AU2012230809B2/en active Active
- 2012-03-22 ES ES12760157T patent/ES2699532T3/es active Active
-
2018
- 2018-01-12 US US15/869,970 patent/US11185585B2/en active Active
-
2021
- 2021-10-27 US US17/512,500 patent/US20220111045A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ohri et al. | Radiotherapy for hepatocellular carcinoma: new indications and directions for future study | |
| Gingis-Velitski et al. | Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice | |
| Cho et al. | Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo | |
| JP2012067116A5 (enExample) | ||
| US20220054563A1 (en) | Dosing regime and formulations for type b adenoviruses | |
| JP2017502017A5 (enExample) | ||
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
| JP2016530323A5 (enExample) | ||
| JP2011116755A5 (enExample) | ||
| JP2008507536A5 (enExample) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2017506662A5 (enExample) | ||
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| Specenier et al. | Recurrent head and neck cancer: current treatment and future prospects | |
| JP2019532047A5 (enExample) | ||
| Tyczyńska et al. | Treatment strategies of gastric cancer—Molecular targets for anti-angiogenic therapy: A state-of-the-art review | |
| WO2012154587A3 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents | |
| Zhang et al. | Management of castrate resistant prostate cancer—recent advances and optimal sequence of treatments | |
| CN104623663B (zh) | 评估癌症于治疗后情况的方法及其相关应用 | |
| Selvaggi et al. | Wingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities | |
| Hoag et al. | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | |
| BR112013021860A2 (pt) | anticorpo anti-tnfalpha humanizado | |
| Chen et al. | Enhanced theranostic efficacy of 89Zr and 177Lu-labeled aflibercept in renal cancer: a viable option for clinical practice | |
| JP2015506352A5 (enExample) |